**Supplemental Tables**

Table 1S: **Characteristics of patients and controls with successful sputum induction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Controls****subjects** | **Patients****(Total)** | **sIgE-negative Group 1** | **sIgE-positive Group 2** |
| Number | 20 | 23 | 13 | 10 |
| Age (years) | 17±6.3 | 16±7.5 | 17.1±9.1 | 14.6±4.9 |
| Sex (m/w) | 9/11 | 13/10 | 7/6 | 6/4 |
| FVC (%) | 100.35 | 94.4±13.8\* | 88.7±9.7 | 101.9±15.1 |
| FEV1 (%) | 104.8 | 91.2±19.1\* | 85.5±17.3 | 98.6±19.6 |
| eNO | 14.9±7.1 | 9.8±3.4 | 8,22±2.4 | 11.38±4,4 |
| Total IgE (KU/L) | 72.5±44.2 | 132.7±205.7 | 36.5±34.5 | 257.9±266.6 \*\* |
| Specific IgE *A.* *fumigatus* (KU/L) | 0.1±0.1  | 8.1±14.3 | 0.1±0.1 | 18.4±17.0\*\* |
| Eosinophils (µl) | n.d. | 172.2±111.6 | 126.2±103.2 | 232.0±96.0 |
| Pseudomonas | N.A. | 4 | 2 | 2 |

For all parameters, mean ± SD are shown; significant differences were found between all patients and controls for FVC and FEV1 (\* p<0.05) and for total IgE and sIgE between the sIgE-negative and sIgE-positive patient group (\*\* p< 0.01).

Table 2S: **Specific RT2 qPCR Primer Assays**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Target mRNA** | **Accession-Number** | **Supplier** | **Catalog Number** | **Product** **Number** |
| **GAPDH** | NM\_001256799 | Qiagen | PPH00150F | 330001 |
| **IL-5** | NM\_000879 | Qiagen | PPH00692B | 330001 |
| **IL-8** | NM\_000584 | Qiagen | PPH00568A | 330001 |
| **IL-13** | NM\_002188 | Qiagen | PPH00688F | 330001 |
| **T-bet** | NM\_013351 | Qiagen | PPH00396A | 330001 |
| **GATA-3** | NM\_001002295 | Qiagen | PPH02143A | 330001 |
| **FoxP3** | NM\_014009 | Qiagen | PPH00029C | 330001 |

Target mRNA, accession-number, supplier, and the catalog number are shown.